Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Transplant Toxicities

Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

Bone Marrow Transplantation volume 50, pages 95–99 (2015)Cite this article

Subjects

Abstract

Numerous studies have reported the feasibility and safety of autologous SCT (ASCT) in patients with multiple myeloma (MM) and mild to moderate renal impairment, but there are limited data in dialysis-dependent patients. In this retrospective study, we reviewed the toxicities and efficacy outcomes of 33 MM patients with dialysis-dependent renal failure who underwent ASCT at our institution from 1998 to 2012. The most common grade 3 non-hematologic toxicities were mucositis (49%), infection (15%) and bleeding (6%). Atrial dysrhythmias (24%) and delirium (30%) of all grades were also common. Hematologic toxicities included febrile neutropenia (88%); and RBC and platelet transfusions were required by 71 and 100% of patients, respectively. Transplant-related mortality (TRM) was high at 15%, predominantly caused by septic shock. Response to ASCT was at least VGPR (very good PR) in 50%, PR in 46.2% and stable disease (SD) in 3.8%. Median OS was 5.6 years, comparable to our overall institutional data. Overall, seven patients became dialysis independent. We conclude that ASCT can be an effective treatment for dialysis-dependent MM patients, with high response rates and survival. However, toxicities and a high TRM are observed indicating that further studies are needed to enhance the safety of this approach.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65.

    CAS  PubMed  Google Scholar 

  3. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7–11.

    CAS  PubMed  Google Scholar 

  4. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Int Med 1998; 158: 1889–1893.

    Article  CAS  Google Scholar 

  5. Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181.

    Article  CAS  PubMed  Google Scholar 

  6. Alexanian R, Barlogie B, Dixon D . Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Int Med 1990; 150: 1693–1695.

    Article  CAS  Google Scholar 

  7. Clark AD, Shetty A, Soutar R . Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999; 13: 79–90.

    Article  CAS  PubMed  Google Scholar 

  8. Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310–1313.

    Article  CAS  PubMed  Google Scholar 

  9. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  PubMed  Google Scholar 

  10. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 812–816.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27–33.

    Article  PubMed  Google Scholar 

  12. Carlson K . Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 2005; 35: 985–990.

    Article  CAS  PubMed  Google Scholar 

  13. Ballester OF, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997; 20: 653–656.

    Article  CAS  PubMed  Google Scholar 

  14. Tosi P, Zamagni E, Tacchetti P, Ceccolini M, Perrone G, Brioli A et al. Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. Biol Blood Marrow Transplant 2010; 16: 1115–1121.

    Article  CAS  PubMed  Google Scholar 

  15. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823–828.

    Article  CAS  PubMed  Google Scholar 

  16. Tauro S, Clark FJ, Duncan N, Lipkin G, Richards N, Mahendra P . Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failure. Bone Marrow Transplant 2002; 30: 471–473.

    Article  CAS  PubMed  Google Scholar 

  17. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol 2006; 134: 385–390.

    Article  CAS  PubMed  Google Scholar 

  18. Cockcroft DW, Gault MH . Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.

    Article  CAS  PubMed  Google Scholar 

  19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  PubMed  Google Scholar 

  20. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

    Article  CAS  PubMed  Google Scholar 

  21. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  22. Prica A, Trieu Y, Xu W, Reece DE, Trudel S, Kukreti V et al. Rapidity and quality of response to steroid-based induction therapy, without the addition of novel agents, does not affect post transplant outcomes in multiple myeloma. Clin Lymphoma Myeloma Leuk 2013; 13: 25–31.

    Article  PubMed  Google Scholar 

  23. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946–2955.

    Article  CAS  PubMed  Google Scholar 

  24. Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012; 120: 1589–1596.

    Article  CAS  PubMed  Google Scholar 

  25. Blanes M, Lahuerta JJ, Gonzalez JD, Ribas P, Solano C, Alegre A et al. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. Biol Blood Marrow Transplant 2013; 19: 69–74.

    Article  CAS  PubMed  Google Scholar 

  26. Cornell CJ Jr, McIntyre OR, Kochwa S, Weksler BB, Pajak TF . Response to therapy in IgG myeloma patients excreting lambda or kappa light chains: CALGB experience. Blood 1979; 54: 23–29.

    PubMed  Google Scholar 

  27. Shustik C, Bergsagel DE, Pruzanski W . Kappa and lambda light chain disease: survival rates and clinical manifestations. Blood 1976; 48: 41–51.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

    R St Bernard, L Chodirker, E Masih-Khan, N Franke, V Kukreti, R Tiedemann, S Trudel, D Reece & C I Chen

  2. Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

    H Jiang

Authors
  1. R St Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Chodirker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Masih-Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Franke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V Kukreti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Tiedemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Trudel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D Reece
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C I Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C I Chen.

Ethics declarations

Competing interests

Drs Kukreti, Tiedemann, Reece and Chen have received research funding and honoraria from Celgene and Janssen, Inc.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

St Bernard, R., Chodirker, L., Masih-Khan, E. et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant 50, 95–99 (2015). https://doi.org/10.1038/bmt.2014.226

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.226

This article is cited by

Search

Advanced search

Quick links